Zarour HM - Search Results

1

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, Wolchok JD. Slingluff CL, et al. Among authors: zarour hm. Oncoimmunology. 2021 Mar 26;10(1):1898105. doi: 10.1080/2162402X.2021.1898105. Oncoimmunology. 2021. PMID: 33796406 Free PMC article. Clinical Trial.

2

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Zarour HM, et al. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5. doi: 10.1073/pnas.97.1.400. Proc Natl Acad Sci U S A. 2000. PMID: 10618430 Free PMC article.

3

Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.

Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ. Ranieri E, et al. Immunol Invest. 2000 May;29(2):121-5. doi: 10.3109/08820130009062294. Immunol Invest. 2000. PMID: 10854179 No abstract available.

4

Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.

Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Herr W, et al. Blood. 2000 Sep 1;96(5):1857-64. Blood. 2000. PMID: 10961887 Free article.

5

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. Zarour HM, et al. Cancer Res. 2000 Sep 1;60(17):4946-52. Cancer Res. 2000. PMID: 10987311

6

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. Zarour HM, et al. Cancer Res. 2002 Jan 1;62(1):213-8. Cancer Res. 2002. PMID: 11782380

7

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Among authors: zarour hm. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.

8

Melanoma vaccines: early progress and future promises.

Zarour HM, Kirkwood JM. Zarour HM, et al. Semin Cutan Med Surg. 2003 Mar;22(1):68-75. doi: 10.1053/sder.2003.50006. Semin Cutan Med Surg. 2003. PMID: 12773015 Review.

9

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM. Mandic M, et al. Among authors: zarour hm. Cancer Res. 2003 Oct 1;63(19):6506-15. Cancer Res. 2003. PMID: 14559844

10

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. Mandic M, et al. Among authors: zarour hm. J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751. J Immunol. 2005. PMID: 15661941

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters